@FierceMedDev: Baxter will keep its sprawling medical products arm and spin off its biopharmaceuticals into a separate company. More | Follow @FierceMedDev
@MarkHFierce: Zyomyx grabs some funding to launch its HIV/AIDS test in emerging markets. More via FierceDiagnostics | Follow @MarkHFierce
@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. Article via FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Supercomputer from "Jeopardy" game show will help scientists read mutations, find drug cocktail for cancer. Story via New York Times | Follow @EmilyWFierce
> Nasdaq has halted trading of Exact Sciences ($EXAS) stock, even as the company meets with an FDA panel of experts on March 27 to discuss a PMA application for its stool DNA-based non-invasive colorectal cancer-screening test. Release
> Guided Therapeutics wants to meet with the FDA within the next two to three months to talk about a PMA approval pathway for its cervical scan diagnostic device. Release
> Vasomedical, a New York maker of medical devices and diagnostic imaging products, said it boosted revenue and reduced net losses in 2013. Release
> California's ArtVentive Medical Group is rolling out a new catheter-assisted endovascular tumor treatment system. Release
> Canada's Neovasc has raised $22.5 million in new equity funding, money that will be used, in part, to help propel development of its cardiac implants. Story
> After three FDA rejections, partners Alimera Sciences ($ALIM) and pSivida ($PSDV) are again submitting their drug-device combo for approval. More
Biotech News
@FierceBiotech: ICYMI: GlaxoSmithKline joins a biotech brain trust to make R&D more efficient. News | Follow @FierceBiotech
@JohnCFierce: I'll be curious to see how Novartis does with the early application on 'breakthrough' drug. Looks promising. Story | Follow @JohnCFierce
@DamianFierce: Brief on $BAX's breakup: creates a $6B biopharma player with focus on bleeding disorders, immune deficiencies. More | Follow @DamianFierce
@EmilyMFierce: Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. News | Follow @EmilyMFierce
> Exelixis' shares flogged after lead drug disappoints at interim PhIII point. More
> RuiYi banks $15M from A-list backers to amp up Chinese R&D. Article
Pharma News
@FiercePharma: Colorado vaccine bill: Necessary education or treating parents like 'idiots'? - Fierce Vaccines. Story | Follow @FiercePharma
@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. More | Follow @TracyStaton
@EricPFierce: FDA 's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. News | Follow @EricPFierce
@CarlyHFierce: ICYMI, here's that link again to yesterday's full issue of FiercePharmaMarketing. It includes a walking bladder. More | Follow @CarlyHFierce
> Drugmakers agree to new FDA rules restricting antibiotic use in livestock. Article
> Worried about legal jeopardy, Merck, GlaxoSmithKline halt copay help for Obamacare patients. News
> New NICE evals could green-light more drugs, but only at 'the very best price.' Story
Pharma Manufacturing News
> Baxter, FDA scramble to overcome shortage of nitroglycerin. News
> GSK says someone tampered with alli bottles. News
> FDA takes aim at yet another Indian API maker. Story
> Market force may put quality at forefront of all generics makers. Article
> FDA's Woodcock throws cold water on generic drug research. Story
> French CMO Novacep sees growth. Brief
Vaccines News
> 'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero. Story
> PhIII fail further dents hopes for GSK's cancer vaccine. Story
> Colorado vaccine bill: Necessary education or treating parents like 'idiots'? Article
> Novartis' Bexsero wins U.K. recommendation in government U-turn. News
> Government H5N1 vaccine orders drive jump in sales at Sinovac. Story
> Buzz: Baxter is considering selling its vaccine unit. Brief